SAN FRANCISCO, CA – June 2, 2025 – BioPalace (the “Company” or “BioPalace”), a new royalty financing platform for the life sciences industry, has officially launched to help biotech and pharmaceutical companies access non-dilutive capital by monetizing future royalty and milestone revenue streams. The platform offers a scalable alternative to traditional equity and debt financing, giving drug developers a path to raise funding while preserving ownership and control.
As capital markets tighten, many promising biotech companies are being forced to make painful decisions—from layoffs and pipeline reprioritizations to complete shutdowns—even when their science shows strong potential for meaningful patient impact. BioPalace aims to address this structural funding gap by providing companies with access to non-dilutive, royalty-based capital, while simultaneously opening the door to a broader pool of investors traditionally excluded from this corner of healthcare finance.
In a space long dominated by a small circle of institutional players, BioPalace expands access on both sides of the market to build a more resilient, inclusive model for financing therapeutic innovation.
“We created BioPalace to support the companies doing some of the hardest, most important work in medicine,” said Husein Hassan, founder of BioPalace and former healthcare investment banker and private equity investor. “Too often, teams with transformative science are forced to give up control or shut down altogether due to inflexible capital models. Our platform offers a more flexible alternative that helps companies raise capital while sustaining and accelerating patient access to the best possible medicines.”
BioPalace structures and facilitates royalty-based funding agreements, with an initial focus on late-stage and commercial-stage therapies that have defined or near-term revenue potential. Each opportunity will undergo rigorous scientific, financial, and legal diligence before being made available to qualified investors.
The Company is currently onboarding its first cohort of biotech partners and expects to open select investment opportunities to investors later this year.
About BioPalace
BioPalace is a royalty financing platform designed to help biotech companies raise non-dilutive capital by transforming future revenue streams into present-day funding. Its mission is to unlock capital for life-saving therapies while opening access for a broader range of accredited and institutional investors to participate in healthcare royalties—an asset class historically reserved for a small circle of insiders. To learn more about how BioPalace is helping biotech companies scale through royalty-based capital, visit www.biopalace.com.
Company Contact
Husein Hassan
Founder & CEO
T: +1 (310) 989-0190
E: husein@biopalace.com
Forward-Looking Statements
This press release may contain forward-looking statements, including but not limited to statements regarding future product offerings, investor participation, business development plans, and market opportunities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. BioPalace undertakes no obligation to update any forward-looking statements except as required by applicable law.
Legal Notice
This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. No offer to buy securities is being solicited, and no such offer will be accepted without compliance with applicable securities laws and delivery of appropriate offering materials. Any securities offerings referenced herein, if made, will be conducted in compliance with applicable securities laws, including Regulation D under the Securities Act of 1933, and will be offered only to investors who are verified as accredited investors within the meaning of Rule 501(a) of Regulation D. BioPalace does not operate as a registered broker-dealer or investment adviser. All securities-related activities, including introductions between issuers and investors, are or will be conducted through appropriately licensed intermediaries or under applicable regulatory exemptions. BioPalace is also exploring compliant frameworks that may, in the future, permit broader investor participation—including offerings under Regulation CF or Regulation A. Any such future public offerings will only be made pursuant to a qualified offering statement filed with the SEC or through a registered intermediary, and only in jurisdictions where lawful. Investments in royalty-based assets are speculative, may involve significant risk, and may be illiquid or difficult to transfer. There is no guarantee of returns or liquidity. Investors should conduct their own due diligence and consult with their own legal, tax, and financial advisors before making any investment decisions.
